Abstract
A substantial number of relapses derive from the NCI standard risk population. CCG-1991 tested two components of the successful COG augmented “BFM” regimen (
N Engl J Med
1998
; 338
:1663
Induction | Consolidation | Interim Maintenance | Delayed Intensification (DI #1) | Interim Maintenance | ||
Reg O Oral MP/M/D | Reg O Oral 6MP/M/D | Maintenance | ||||
DI #2 | Maintenance | |||||
Reg I V/IV M | Reg I V/IV M | Maintenance | ||||
DI #2 | Maintenance |
Induction | Consolidation | Interim Maintenance | Delayed Intensification (DI #1) | Interim Maintenance | ||
Reg O Oral MP/M/D | Reg O Oral 6MP/M/D | Maintenance | ||||
DI #2 | Maintenance | |||||
Reg I V/IV M | Reg I V/IV M | Maintenance | ||||
DI #2 | Maintenance |
CCG-1991 enrolled a total of 3026 patients between 6/1/00 and 1/31/05 with 2078 eligible randomized non-T ALL patients. The overall 5-year event free (EFS) and overall survival (OS) for the randomized patients was 90.5% (SE = 1.0 %), and 96.0% (SE = 1.0%). We previously reported the double DI randomization (
Blood
2006
; 108
: abstract #146
Disclosures: Matloub:bristol-myers squibb: Employment.
Author notes
Corresponding author
2008, The American Society of Hematology
2008
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal